International Myeloma Working Group shares recommendations for plasma-cell disorders
- Recommendations guide optimal use of new imaging techniques
- Better imaging means earlier intervention and enhanced monitoring of disease
- Roswell Park was early adopter of new guidelines
BUFFALO, N.Y. — Just as newer drugs have significantly improved outcomes for patients with multiple myeloma in the past decade, newer imaging techniques are upgrading detection of the disease, leading to earlier treatment. But standards to help guide clinicians on the optimal use of advanced imaging have lagged behind. Until now.
Jens Hillengass, MD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, led an International Myeloma Working Group (IMWG) effort to compile new recommendations — the first in 10 years — for imaging techniques that offer more sensitive and accurate diagnosis and monitoring for patients with multiple myeloma and other plasma-cell disorders. Multiple myeloma — the second most common type of blood cancer — occurs when white blood cells known as plasma cells multiply out of control.
“Use of newer imaging techniques is changing the whole landscape, from diagnosis to treatment to supportive care to survivorship, and all those things are coming into this direction of research in multiple myeloma right now,” says Dr. Hillengass.
Hillengass and a team of two experts developed the guidelines, which were then reviewed by the entire working group. Their findings have been newly published in the journal The Lancet Oncology.
The guidelines are based in part on an examination of results of computed tomography (CT) and X-ray imaging from several countries. The team found that using only conventional X-ray misses 25% of instances where patients have bone destruction already and need treatment.
“There has to be destruction of 30 to 50% of the bone, sometimes up to 70%, before you see anything on X-ray,” says Hillengass, who is first author on the new guidelines. “More sophisticated imaging is necessary not only in the beginning to assess the disease but also to assess the response and to see what is left after our standard treatment. Myeloma is a disease that can cause focal and diffuse destruction of the bone, and to see that, you need sharp imaging.”
The major change in the new imaging guidelines is that whole-body low-dose CT replaces conventional skeletal survey as the standard imaging technique recommended for assessing bone destruction. The IMWG team recommends that this more sophisticated technique and others, including PET-CT (positron emission tomography) and MRI (magnetic resonance imaging) be introduced generally into clinical practices.
These practices are already employed in the clinical care of myeloma patients at Roswell Park, and a team at the cancer center is conducting a clinical trial to explore what CT-guided biopsies of focal lesions may reveal about the spatial and temporal heterogeneity of this disease.
Dr. Hillengass hopes that broader application of these newer techniques will lead to more refined imaging, more accurate diagnoses, earlier treatments and more patients living longer due to lasting remissions.
“There’s a lot of research underway now exploring whether incorporating more specific tracers or dyes into various imaging techniques will be beneficial, and also to figure out how we can assess minimal residual disease, or very low tumor burdens after treatment,” he notes. “Therefore, we need much higher sensitivity and also functional information that cutting-edge imagery can provide. There are important questions still to be asked as these technologies evolve.”
The International Myeloma Foundation formed the IMWG in 2001 to encourage dialogue and collaboration among the world’s leading myeloma experts. The group includes 243 members from 39 countries who collaboratively conduct research to improve outcomes of the disease and provide scientifically valid consensus opinions regarding its diagnosis and treatment.
The paper, “International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders, is available online at sciencedirect.com.
Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.
Annie Deck-Miller, Senior Media Relations Manager